{"id":"NCT01179516","sponsor":"Takeda","briefTitle":"Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","officialTitle":"A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2012-05","completion":"2012-06","firstPosted":"2010-08-11","resultsPosted":"2013-12-18","lastUpdate":"2013-12-18"},"enrollment":469,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"Vortioxetine","otherNames":["Lu AA21004","Brintellix®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Vortioxetine 10 mg","type":"EXPERIMENTAL"},{"label":"Vortioxetine 15 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.","primaryOutcome":{"measure":"Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","timeFrame":"Baseline and Week 8","effectByArm":[{"arm":"Placebo","deltaMin":-12.87,"sd":1.043},{"arm":"Vortioxetine 10 mg","deltaMin":-13.66,"sd":1.064},{"arm":"Vortioxetine 15 mg","deltaMin":-13.36,"sd":1.087}],"pValues":[{"comp":"OG000 vs OG001","p":"0.597"},{"comp":"OG000 vs OG002","p":"0.745"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":61,"countries":["United States"]},"refs":{"pmids":["26035186"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":160},"commonTop":["Nausea","Headache","Dry mouth","Constipation","Diarrhoea"]}}